Fibrinogen/albumin ratio index is an independent predictor of recurrence-free survival in patients with intrahepatic cholangiocarcinoma following surgical resection.
Albumin
Fibrinogen
Fibrinogen-to-albumin ratio
Intrahepatic cholangiocarcinoma
Prognosis
Surgery
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
20 Jul 2021
20 Jul 2021
Historique:
received:
31
03
2021
accepted:
08
07
2021
entrez:
21
7
2021
pubmed:
22
7
2021
medline:
23
7
2021
Statut:
epublish
Résumé
Systemic inflammation and nutritional status are associated with tumor development and progression. This study investigated the prognostic value of fibrinogen/albumin ratio index (FARI) in predicting recurrence-free survival (RFS) in patients with intrahepatic cholangiocarcinoma (ICC) undergoing hepatectomy. A retrospective cohort was conducted including patients who received curative hepatectomy for ICC at our hospital between May 2010 and December 2016. We collected the preoperative hematologic parameters and clinical data of all patients. Time-dependent receiver operating characteristic curve was used to identify the optimal cutoff value of FARI. The association between FARI-high and FARI-low group was investigated by using the Kaplan-Meier method. A nomogram based on the results of univariate and multivariate analysis was established. A total of 394 patients with ICC who underwent hepatectomy at our hospital were enrolled. K-M analysis revealed that increased FARI was related to reduced RFS (P < 0.001). The multivariate analysis indicated that tumor number, tumor-node-metastasis stage, lymph node metastasis, cirrhosis, serum carbohydrate antigen 19-9, and FARI were independent predictors of RFS, and the ROC curve analysis showed that the optimal cutoff value for FARI was 0.084 based on the Youden index. The nomogram for FARI showed satisfactory accuracy in predicting RFS for ICC patients undergoing hepatectomy (C index = 0.663; AIC = 3081.07). Preoperative FARI is an independent predictor of RFS in patients undergoing hepatectomy for ICC, and the nomogram can be useful for clinical decision-making in the postoperative management of these patients.
Sections du résumé
BACKGROUND
BACKGROUND
Systemic inflammation and nutritional status are associated with tumor development and progression. This study investigated the prognostic value of fibrinogen/albumin ratio index (FARI) in predicting recurrence-free survival (RFS) in patients with intrahepatic cholangiocarcinoma (ICC) undergoing hepatectomy.
METHODS
METHODS
A retrospective cohort was conducted including patients who received curative hepatectomy for ICC at our hospital between May 2010 and December 2016. We collected the preoperative hematologic parameters and clinical data of all patients. Time-dependent receiver operating characteristic curve was used to identify the optimal cutoff value of FARI. The association between FARI-high and FARI-low group was investigated by using the Kaplan-Meier method. A nomogram based on the results of univariate and multivariate analysis was established.
RESULTS
RESULTS
A total of 394 patients with ICC who underwent hepatectomy at our hospital were enrolled. K-M analysis revealed that increased FARI was related to reduced RFS (P < 0.001). The multivariate analysis indicated that tumor number, tumor-node-metastasis stage, lymph node metastasis, cirrhosis, serum carbohydrate antigen 19-9, and FARI were independent predictors of RFS, and the ROC curve analysis showed that the optimal cutoff value for FARI was 0.084 based on the Youden index. The nomogram for FARI showed satisfactory accuracy in predicting RFS for ICC patients undergoing hepatectomy (C index = 0.663; AIC = 3081.07).
CONCLUSION
CONCLUSIONS
Preoperative FARI is an independent predictor of RFS in patients undergoing hepatectomy for ICC, and the nomogram can be useful for clinical decision-making in the postoperative management of these patients.
Identifiants
pubmed: 34284775
doi: 10.1186/s12957-021-02330-2
pii: 10.1186/s12957-021-02330-2
pmc: PMC8293519
doi:
Substances chimiques
Albumins
0
Fibrinogen
9001-32-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
218Subventions
Organisme : national natural science foundation of china
ID : 81972747
Informations de copyright
© 2021. The Author(s).
Références
World J Surg Oncol. 2020 Dec 4;18(1):319
pubmed: 33276780
J Hepatobiliary Pancreat Sci. 2018 Apr;25(4):240-248
pubmed: 29450978
Ann Surg Oncol. 2019 Oct;26(11):3682-3692
pubmed: 31264117
Front Oncol. 2020 Aug 18;10:1459
pubmed: 33014783
Blood. 2005 Jan 1;105(1):178-85
pubmed: 15367435
J Cancer. 2018 Jan 1;9(1):189-197
pubmed: 29290785
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Hepatol. 2014 Jun;60(6):1268-89
pubmed: 24681130
World J Gastroenterol. 2015 Apr 28;21(16):4961-8
pubmed: 25945010
Br J Cancer. 2016 Apr 26;114(9):965-71
pubmed: 27115567
Eur J Oncol Nurs. 2005;9 Suppl 2:S39-50
pubmed: 16437757
J Surg Oncol. 2017 May;115(6):696-703
pubmed: 28194791
J Cancer Res Clin Oncol. 2017 Dec;143(12):2413-2424
pubmed: 28801734
World J Surg Oncol. 2020 Jan 13;18(1):9
pubmed: 31931816
J Immunol Res. 2018 May 22;2018:4925498
pubmed: 30027102
J Gastrointest Surg. 2020 Apr;24(4):786-795
pubmed: 31012045
World J Surg Oncol. 2020 Nov 23;18(1):303
pubmed: 33228682
Onco Targets Ther. 2016 Aug 24;9:5317-28
pubmed: 27601923
Surg Oncol Clin N Am. 2014 Apr;23(2):231-46
pubmed: 24560108
JAMA Oncol. 2020 Sep 1;6(9):1405-1409
pubmed: 32729929
Surgery. 2012 Feb;151(2):213-22
pubmed: 21975289
World J Gastroenterol. 2020 Apr 7;26(13):1501-1512
pubmed: 32308350
World J Surg Oncol. 2021 Apr 10;19(1):107
pubmed: 33838682
Lancet Oncol. 2019 May;20(5):663-673
pubmed: 30922733
J Thromb Haemost. 2008 Jan;6(1):176-83
pubmed: 17949478
Anticancer Res. 2017 Jan;37(1):183-190
pubmed: 28011489
Nat Rev Clin Oncol. 2018 Feb;15(2):95-111
pubmed: 28994423
Acta Paediatr. 2007 May;96(5):644-7
pubmed: 17376185
Crit Rev Oncol Hematol. 2017 Dec;120:203-209
pubmed: 29198333
Liver Int. 2019 May;39 Suppl 1:19-31
pubmed: 30851228
Oncotarget. 2015 Nov 10;6(35):38410-20
pubmed: 26334098
Cancer Treat Rev. 2012 May;38(3):218-25
pubmed: 21763074
Stat Med. 1996 Feb 28;15(4):361-87
pubmed: 8668867
World J Surg Oncol. 2021 May 7;19(1):142
pubmed: 33962620
J Cancer. 2018 Jun 12;9(13):2341-2348
pubmed: 30026830
Clin Chim Acta. 2018 Jan;476:81-91
pubmed: 29170102
Front Oncol. 2020 Apr 28;10:525
pubmed: 32411593
Clin Nutr. 2019 Oct;38(5):2423-2429
pubmed: 30471794
Clin Nutr. 2017 Feb;36(1):11-48
pubmed: 27637832
Clin Nutr. 2019 Apr;38(2):644-651
pubmed: 29789167
Br J Clin Pharmacol. 2004 Jun;57(6):695-713
pubmed: 15151515
World J Surg Oncol. 2020 Oct 23;18(1):272
pubmed: 33097053
HPB (Oxford). 2019 Dec;21(12):1656-1666
pubmed: 31307889
Am J Physiol Gastrointest Liver Physiol. 2001 Sep;281(3):G705-17
pubmed: 11518683
World J Surg Oncol. 2021 Mar 11;19(1):69
pubmed: 33706789
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
World J Surg Oncol. 2021 Feb 22;19(1):59
pubmed: 33618734
J Clin Oncol. 2013 Mar 20;31(9):1188-95
pubmed: 23358969
Ann N Y Acad Sci. 2001;936:406-25
pubmed: 11460495